{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:25:30Z","timestamp":1790612730235,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018502","name":"Kanazawa University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018502","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of immune checkpoint inhibitors has increased in the field of oncology; however, various immune-related adverse events affecting multiple organs have been reported. Herein, we present a case of concurrent hepatitis, cholangitis, and pancreatitis as immune-related adverse events (irAE); a case of autoimmune disease due to oncologic immunotherapy. A man in his 80s who was undergoing pembrolizumab therapy for recurrent renal pelvic cancer presented to the emergency department with a loss of appetite. Laboratory tests revealed elevated levels of inflammatory markers and liver enzymes. Initial non-contrast computed tomography (CT) suggested cholecystitis and cholangitis, for which antibiotics were administered. However, because of poor improvement, contrast-enhanced dynamic CT and gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid-enhanced magnetic resonance imaging (MRI) were performed two weeks after visiting the emergency department to reassess the underlying cause. In these examinations, besides the bile dust wall thickening and edematous changes along Glisson\u2019s sheath suggesting the cholangitis, inflammatory enlargement in pancreatic tail was also revealed. Considering these imaging findings suggesting the cholangitis and pancreatitis during pembrolizumab therapy, irAE was suspected as the cause of symptoms. A liver biopsy subsequently performed strongly indicated hepatitis and cholangitis as irAE. Based on these findings, concurrent hepatitis, cholangitis, and pancreatitis as irAE by pembrolizumab were diagnosed. Imaging findings of irAE cholangitis are similar to those of primary sclerosing cholangitis and IgG4-related cholangitis. Particularly in cases like this one, where pancreatitis is also present. However, if a history of immune checkpoint inhibitor use is known, it is possible to include irAE in the differential diagnosis, as observed in this case. Therefore, by keeping the use of immune checkpoint inhibitors in mind during imaging interpretation, imaging examinations could be a clue to suggest the possibility of irAE. Recognizing the imaging findings associated with irAEs and the existence of cases where irAE cholangitis and irAE pancreatitis coexist, it can aid earlier diagnosis of irAEs.<\/jats:p>","DOI":"10.1007\/s00261-025-04994-w","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:54:54Z","timestamp":1748325294000},"page":"5845-5851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Case of simultaneous occurrence of hepatitis, cholangitis, and pancreatitis as immune-related adverse events induced by immune checkpoint inhibitor therapy: a case report"],"prefix":"10.1007","volume":"50","author":[{"given":"Kana","family":"Kawata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Toshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Kozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"4994_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4994_CR2","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","volume":"69","author":"L Parlati","year":"2018","unstructured":"Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, Mallet V; CERTIM group (2018) Incidence of grade 3\u20134 liver injury under immune checkpoints inhibitors: A retrospective study. J Hepatol 69(6):1396\u20131397. https:\/\/doi.org\/10.1016\/j.jhep.2018.08.014","journal-title":"J Hepatol"},{"issue":"4","key":"4994_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35(4):529\u2013536. https:\/\/doi.org\/10.1007\/s10637-017-0453-0","journal-title":"Invest New Drugs"},{"issue":"4","key":"4994_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","volume":"19","author":"J George","year":"2019","unstructured":"George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, Price C, Farrell JJ (2019) Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology. 19(4):587\u2013594. https:\/\/doi.org\/10.1016\/j.pan.2019.04.015.","journal-title":"Pancreatology."},{"key":"4994_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.crad.2017.04.003","volume":"72","author":"F Alessandrino","year":"2017","unstructured":"Alessandrino F, Tirumani SH, Krajewski KM, Shinagare AB, Jagannathan JP, Ramaiya NH, Di Salvo DN (2017) Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol 72:521\u2013533. https:\/\/doi.org\/10.1016\/j.crad.2017.04.003","journal-title":"Clin Radiol"},{"key":"4994_CR6","doi-asserted-by":"publisher","first-page":"20200663","DOI":"10.1259\/bjr.20200663","volume":"94","author":"MA Anderson","year":"2021","unstructured":"Anderson MA, Kurra V, Bradley W, Kilcoyne A, Mojtahed A, Lee SI (2021) Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. Br J Radiol 94:20200663. https:\/\/doi.org\/10.1259\/bjr.20200663","journal-title":"Br J Radiol"},{"key":"4994_CR7","doi-asserted-by":"publisher","first-page":"e00667","DOI":"10.14309\/ctg.0000000000000667","volume":"15","author":"Y Hori","year":"2024","unstructured":"Hori Y, Naitoh I, Naiki-Ito A, Kawai T, Yoshida M, Kato A, Kachi K, Sahashi H, Adachi A, Toyohara T, Kito Y, Yamamoto T, Takahashi S, Kataoka H (2024) Incidence of pancreatic injury and pancreatitis in patients treated with immune checkpoint inhibitors. Clin Transl Gastroenterol 15:e00667. https:\/\/doi.org\/10.14309\/ctg.0000000000000667","journal-title":"Clin Transl Gastroenterol"},{"key":"4994_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11604-023-01505-z","volume":"42","author":"S Ichikawa","year":"2024","unstructured":"Ichikawa S, Goshima S (2024) Key CT and MRI findings of drug-associated hepatobiliary and pancreatic disorders. Jpn J Radiol 42:235\u2013245. https:\/\/doi.org\/10.1007\/s11604-023-01505-z","journal-title":"Jpn J Radiol"},{"key":"4994_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H (2020) Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 26:353\u2013365. https:\/\/doi.org\/10.3748\/wjg.v26.i3.353","journal-title":"World J Gastroenterol"},{"key":"4994_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR (2020) Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology 72:315\u2013329. https:\/\/doi.org\/10.1002\/hep.31227","journal-title":"Hepatology"},{"key":"4994_CR11","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1007\/s10637-021-01136-z","volume":"39","author":"M Takinami","year":"2021","unstructured":"Takinami M, Ono A, Kawabata T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Endo M, Kiyohara Y, Yasui H, Niwakawa M, Takahashi T (2021) Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Investig New Drugs 39:1716\u20131723. https:\/\/doi.org\/10.1007\/s10637-021-01136-z","journal-title":"Investig New Drugs"},{"key":"4994_CR12","doi-asserted-by":"publisher","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","volume":"131","author":"JP Das","year":"2020","unstructured":"Das JP, Postow MA, Friedman CF, Do RK, Halpenny DF (2020) Imaging findings of immune checkpoint inhibitor associated pancreatitis. Eur J Radiol 131:109250. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109250","journal-title":"Eur J Radiol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-04994-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-04994-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-04994-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:04:10Z","timestamp":1762880650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-025-04994-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4994"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-04994-w","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}